Clinical Trial Update: Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of pentostatin, alemtuzumab, and rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)
• NIPENT (pentostatin)
• Rituxan (rituximab)

Snippet

Sponsor: Mayo Clinic | Conditions: Leukemia, Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2014-06-20